NVS - Tenax Therapeutics a buy at RothMKM due to late-stage pulmonary hypertension assets
2023-03-07 15:26:11 ET
- RothMKM has initiated Tenax Therapeutics ( NASDAQ: TENX ) with a buy saying that the company's two phase 3-ready assets for pulmonary hypertension conditions could drive growth for the company.
- The firm has a $6 price target (823% upside based on Monday's close).
- Analyst Jonathan Aschoff said that of the two late-stage assets, TNX-103, a novel oral formulation of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), is the bigger value driver. The condition is currently without any approved medication.
- The other candidate, TNX-201, is a better tolerated version of oral imatinib -- Novartis' ( NVS ) Gleevec -- for pulmonary arterial hypertension.
- Seeking Alpha's Quant Rating views Tenax ( TENX ) as a strong sell.
For further details see:
Tenax Therapeutics a buy at RothMKM due to late-stage pulmonary hypertension assets